These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 34512630)

  • 21. Identification of tumor antigens and immune subtypes of acute myeloid leukemia for mRNA vaccine development.
    Wang F
    Clin Transl Oncol; 2023 Jul; 25(7):2204-2223. PubMed ID: 36781600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening of Tumor Antigens and Construction of Immune Subtypes for mRNA Vaccine Development in Head and Neck Squamous Cell Carcinoma.
    Li HX; Liu TR; Tu ZX; Xie CB; Wen WP; Sun W
    Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LRP2 and DOCK8 Are Potential Antigens for mRNA Vaccine Development in Immunologically 'Cold' KIRC Tumours.
    Zhang S; Xia K; Chang Y; Wei Y; Xiong Y; Tang F; Peng J; Ouyang Y
    Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of lung adenocarcinoma tumor antigens and ferroptosis subtypes for developing mRNA vaccines.
    Chen Y; Zhang C; Li Y; Tan X; Li W; Tan S; Liu G
    Sci Rep; 2024 Feb; 14(1):3219. PubMed ID: 38331967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine.
    Ping H; Yu W; Gong X; Tong X; Lin C; Chen Z; Cai C; Guo K; Ke H
    Invest New Drugs; 2022 Dec; 40(6):1173-1184. PubMed ID: 35962880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of Five Tumor Antigens for Development and Two Immune Subtypes for Personalized Medicine of mRNA Vaccines in Papillary Renal Cell Carcinoma.
    Hu J; Yuan Z; Jiang Y; Mo Z
    J Pers Med; 2023 Feb; 13(2):. PubMed ID: 36836593
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel risk score system based on immune subtypes for identifying optimal mRNA vaccination population in hepatocellular carcinoma.
    Zhuang H; Tang C; Lin H; Zhang Z; Chen X; Wang W; Wang Q; Tan W; Yang L; Xie Z; Wang B; Chen B; Shang C; Chen Y
    Cell Oncol (Dordr); 2024 Aug; 47(4):1205-1220. PubMed ID: 38315287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of Novel Tumor Antigens and the Immune Landscapes of Bladder Cancer Patients for mRNA Vaccine Development.
    Wang G; Gao Y; Chen Y; Wang K; Zhang S; Li G
    Front Oncol; 2022; 12():921711. PubMed ID: 35814377
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identifying tumor antigens and immuno-subtyping in colon adenocarcinoma to facilitate the development of mRNA vaccine.
    Tan H; Yu T; Liu C; Wang Y; Jing F; Ding Z; Liu J; Shi H
    Cancer Med; 2022 Dec; 11(23):4656-4672. PubMed ID: 35593226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive Panel for Immunotherapy in Low-Grade Glioma.
    Lv Q; Zhang Z; Fu H; Li D; Liu Y; Sun Y; Wu M
    World Neurosurg; 2024 Mar; 183():e825-e837. PubMed ID: 38216032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identifying Potential Tumor Antigens and Antigens-Related Subtypes in Hepatocellular Carcinoma for mRNA Vaccine Development.
    Liao W; Shi Z; Tang H; Wu T; Zhang C; He Y; Zou R; Wang L
    J Oncol; 2022; 2022():6851026. PubMed ID: 36072981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential tumor-specific antigens and immune landscapes identification for mRNA vaccine in thyroid cancer.
    Wang X; Wang G; Xu Q; Li Y; Song W; Liu Z; Tian Y; Wang L; Zhao K; Wang Y
    Front Oncol; 2024; 14():1480028. PubMed ID: 39403328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of tumor-antigen signatures and immune subtypes for messenger RNA vaccine selection in advanced clear cell renal cell carcinoma.
    Xu Z; Wu Y; Chen X; Jin B
    Surgery; 2024 Sep; 176(3):785-797. PubMed ID: 38851900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peptide-based immunotherapeutic approaches to glioma: a review.
    Yamanaka R; Itoh K
    Expert Opin Biol Ther; 2007 May; 7(5):645-9. PubMed ID: 17477802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of Tumor Antigens and Immune Landscape in Glioblastoma for mRNA Vaccine Development.
    Ye L; Wang L; Yang J; Hu P; Zhang C; Tong S; Liu Z; Tian D
    Front Genet; 2021; 12():701065. PubMed ID: 34527020
    [No Abstract]   [Full Text] [Related]  

  • 36. Immunotherapeutic advances in glioma management: The rise of vaccine-based approaches.
    Andrew Awuah W; Shah MH; Tan JK; Ranganathan S; Sanker V; Darko K; Tenkorang PO; Adageba BB; Ahluwalia A; Shet V; Aderinto N; Kundu M; Abdul-Rahman T; Atallah O
    CNS Neurosci Ther; 2024 Sep; 30(9):e70013. PubMed ID: 39215399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glioma antigen.
    Toda M
    Adv Exp Med Biol; 2012; 746():77-84. PubMed ID: 22639160
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of Lower Grade Glioma Antigens Based on Ferroptosis Status for mRNA Vaccine Development.
    Zhao Z; Xing N; Guo H; Li J; Sun G
    Pharmgenomics Pers Med; 2024; 17():105-123. PubMed ID: 38623558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glioma-specific antigens for immune tumor therapy.
    Skog J
    Expert Rev Vaccines; 2006 Dec; 5(6):793-802. PubMed ID: 17184218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune Classification and Immune Landscape Analysis of Triple-Negative Breast Cancer.
    Hu S; Qu X; Jiao Y; Hu J; Wang B
    Front Genet; 2021; 12():710534. PubMed ID: 34795691
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.